Serum β2—Microglobulin Levels in Patients with Various Solid Cancer

Kesheng Li1*, Huifeng Du1, Xiaowen Lian1, Ming Yuan1, Qinjiang Liu2, Suisheng Yang3, Xuezhong Chen1, Rong Yang3 and Wenhua Ye1

1Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province, Lanzhou, China
2Department of Otorhinolaryngology, Tumor Hospital of Gansu province, Lanzhou, China
3Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province, Lanzhou, China

Abstract

Background: The level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain cancers. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancers, to find the prognostic and predictive value of serum β2-M level elevation in patients with solid cancers.

Methods: A total of 1158 serum samples from 774 patients with various solid cancer and 384 patients with various solid benign tumor patients were analyzed by β2-microglobulin ELISA kit, the data were analyzed by using statistical 36 packages for sciences (spss11.0) software.

Results: In patients with thyroid cancer, patients with breast cancer and that with liver cancer the mean β2-microglobulin levels and positive rate were significantly higher than that in controls (p<0.05, p<0.01). In patients with other solid cancer including gastric, esophagus, intestinal and lung cancer the mean β2-microglobulin levels and the positive rate have no significant difference compared with that in controls (p>0.05, p>0.05), and the positive rats were not significantly different compared with that in controls (p>0.05) except the patients with esophagus cancer in which the positive rate was significantly different compared with that in controls (p<0.01). In female breast cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in breast benign tumor patients (p<0.05, p<0.05), no significant difference stages and clinical stages. In thyroid cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in thyroid benign tumor patients (p<0.05, p<0.01), no significant difference in sex, ages, clinical stages, but the mean β2-microglobulin levels and the positive rate were significantly higher in patients with follicular thyroid cancer than that in patients with papillary thyroid 54 cancer patients.

Conclusion: β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of assistantly diagnostic factors in patients with these cancers.

Introduction

β2-microglobulin is a low molecular weight protein consisting of a single chain of 100 amino acids which is part of the HLA antigen molecule, where it represents the invariant light chain [1,2]. It is expressed on the membrane of almost all nucleated cells, and is detectable in all body fluids as a shedding product of cell membrane [3]. Approximately 50% β2-M is produced by lymphocytes and is filtered freely over the glomeruli. Under normal circumstances, more than 99.9% is reabsorbed in the proximal tubuli of the kidneys and metabolized there. In renal disease with damage to this segment of the nephro, eg. Acute tubuli, increased quantities of β2-M are excreted in the urine. If the rate of glomerular filtration is reduced, serum β2-M is increased and this is also the case in persons with increased cell division despite normal renal function [4]. Therefore, the serum and urine β2-M concentrations are used to monitor glomerular and tubular nephropathies [5], and its level is elevated in patients with certain malignancies, including solid and liquid tumors [6,7]. The increased tissues and serum level of β2-M is associated a high 74 tumor burden and poor prognosis. Thus, the level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain cancers [7-9]. But, the clinical usefulness of measuring serum β2-M in some solid tumors is controversial in the literature [10,11]. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancer.

Patients and Methods

A total of 1158 serum from 774 patients with various solid cancer and 384 patients with various solid benign tumor who were referred to the Tumor Hospital of Gansu province for treatment, proved by clinical and histopathological evidence, and all patients had normal renal function; 1002 serum from healthy individual who were referred to healthy examination center of Ren Min Hospital of Gansu province for physical examination. The patients characteristics and healthy controls are listed in table 1.

Under aseptic precautions venous blood was drawn preoperatively and serum was separated. The samples were frozen at -20°C until assay. The serum was analyzed by Enzyme Linked Immunosorbent Assay (β2-microglobulin ELISA kit, developed by Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province). The data were analyzed by using statistical package for sciences (spss11.0) software, p<0.05 were considered 94 significant.

Results

Mean levels of serum β2-microglobulin in solid cancer patients

In order to get mean β2-microglobulin levels in healthy individual...
to be used as controls and the 2 times mean β2-microglobulin levels in controls was used as cut off. The mean levels of serum β2-microglobulin and the positive rate in patients with various solid cancer and controls are given in table 2. In patients with thyroid, breast and liver cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in controls (p<0.05, figure 1A; p<0.01, figure 1B). In patients with other solid cancer including gastric, esophagus, intestinal and lung cancer the mean β2-microglobulin levels and the positive rats have no significant difference compared with that in controls (p >0.05,figure 1A; p > 0.05; figure 1B), except the esophagus cancer patients in which the positive rate was significantly different compared with that in control (p<0.01; figure 1B).

### Mean levels of serum β2-microglobulin in female patients with breast cancer and breast benign tumor

| Group                | No     | sex | men(ages/years) |
|----------------------|--------|-----|-----------------|
| Controls             | 1002   |     | 559/443 (6-94)  |
| Thyroid Ca.          | 95     |     | 26/69 (17-79)   |
| Thyroid benign-tumors.| 243    |     | 54/189 (8-79)   |
| Breast Ca.           | 205    |     | 4/201 (19-78)   |
| Breast benign-tumors.| 141    |     | 6/135 (2-78)    |
| Liver Ca.            | 77     |     | 57/20 (30-60)   |
| Esophagus Ca.        | 148    |     | 114/34 (25-78)  |
| Intestinal Ca.       | 58     |     | 42/16 (26-84)   |
| LungCa.              | 119    |     | 78/41 (17-80)   |

Table 1: Patients characteristics and healthy controls.

| Group                | No     | Serum β2-M (mg/L) | positive rate | mean ±:SD | P | % | P |
|----------------------|--------|-------------------|---------------|-----------|---|---|---|
| Controls             | 1002   | 0.95±:4.47        | 7.88          |           |   |   |   |
| Thyroid Ca.          | 95     | 2.84±:4.56        | <0.05         | 34.73     | <0.01 | <0.01 | <0.01 |
| Breast Ca.           | 205    | 2.02±:4.78        | <0.05         | 28.29     | <0.01 | <0.01 | <0.01 |
| Liver Ca.            | 77     | 2.81±:6.16        | <0.05         | 23.37     | <0.01 | <0.01 | <0.01 |
| Gastric Ca.          | 148    | 1.25±:5.24        | <0.05         | 11.48     | <0.05 | <0.05 | <0.05 |
| Esophagus Ca.        | 72     | 1.47±:3.20        | <0.05         | 18.05     | <0.01 | <0.01 | <0.01 |
| Intestinal Ca.       | 58     | 1.51±:4.71        | <0.05         | 13.79     | <0.05 | <0.05 | <0.05 |
| LungCa.              | 119    | 0.94±:2.03        | <0.05         | 11.76     | >0.05 | >0.05 | >0.05 |

Table 2: Mean levels of serum β2-microglobulin in Patients with various solid Cancer and controls.

The mean β2-microglobulin levels and the positive rats in female patients with breast cancer and breast 112 benign tumor were analyzed, the 2 times mean β2-microglobulin levels in control were used as its cut off. The results were showed in table 3. In female patients with breast cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in control and patients with breast benign tumor (p<0.05 figure 2A, p<0.05; figure 2B). In patients with breast benign tumor the mean β2-microglobulin level has no significant difference compared with that in control, but the positive rate was significantly higher than that in control (p>0.05 figure 2A: p>0.05, figure 2B). In female patients with breast cancer the mean β2-microglobulin levels have no significant difference at ages and clinical stages, but the positive rate in ages of ≥60 years was significantly lower than that in ages of < 60 years (p<0.01).

### Mean levels of serum β2-microglobulin in patients with thyroid cancer and thyroid benign tumor

The mean β2-microglobulin levels in patients with thyroid cancer and thyroid benign tumor were analyzed, the 2 times mean β2-microglobulin level in controls was used as its cut off, and the results were showed in table 3. In patients with thyroid cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in control and patients with thyroid benign tumor (p<0.05, p<0.01; figure 2C,D), the mean β2-microglobulin levels and the positive rate have no significant difference between controls and patients with thyroid benign tumor (p>0.05, p>0.05: figure 2C,D). In patients with thyroid cancer the mean β2-microglobulin levels and the positive rate have no significant difference at sex, and ages, except the age of 40-60 years in that the positive rate have significant difference compared with that in age <40 years. The mean β2-microglobulin levels and the positive rate have no significant difference in clinical stages I-III (p> 0.05, p>0.05) but having significant difference in clinical
The results demonstrates that serum β2-microglobulin may be valuable marker in the diagnosis of breasts cancer, thyroid cancer, liver cancer and esophagus cancer, but as a independent tumor marker, the clinical valuation of serum level elevating of β2-microglobulin in the diagnosis of gastric cancer, intestinal cancer and lung cancer seems limited, agreeing with the literature [11,12,14].

In order to avoid false positive results and decide the reliable cut off level, the serum level changing of β2-microglobulin of healthy individuals 167 during at different ages and sex were analyzed, the results showed that the β2-M level in healthy individuals have no significant difference in sex and age except the females of ≤ 40 years in whom the β2-M level was significantly lower than that of >40 years, suggesting that when evaluated the β2-M level was used to elevate the positive rate in female patients with cancer, the individual cut off levels was needed.

In female patients with breast cancer the mean β2-microglobulin levels and positive rate have no significant difference at ages, clinical stages and cell type, but the positive was highest in patients of ≤ 40 years, suggesting that detecting serum β2-microglobulin level in patients of ≤ 40 years may have more clinical valuation than that in the patients of > 40 years.

In patients with thyroid cancer the mean β2-microglobulin levels
and positive rate have no significant difference at sex, age and clinical stages but positive was highest in patients in range 40-60 years, and in patients with folliculaire thyroid cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in patients with mamillary thyroid cancer, suggesting that detecting serum β2-microglobulin level in range 40-60 years may have more clinical valuation than that in the patients of 18<40 years and >60 years, and more sensitive in folliculaire thyroid cancer than in other cell type.

Another observation that emerged from the current study is the serum levels elevating of β2-M have no significant diagnostic valuation in thyroid cancer and breast cancer patients of ≥60 years. These observation are not in line with previous report showing that the serum β2-M levels have independent prognostic role in patients with AML who are ≥60 years old [7]. This observation may be explained that the serum β2-M levels elevated in normal individual of ≥60 years under normal physiological condition may be due to the β2-M metabolizing decreasing. Therefore, the serum β2-M level elevating in patients of ≥60 years has no significant difference compared with normal individual.

The mechanism of altered β2-M level is not yet clearly understood. Various Possibilities for increased serum level of β2-M suggested are an increased cellular activity in malignancy being responsible for an increased release of β2-M, β2-M being a constituent of HLA molecules, cell membrane turnover or cell division could increased the shedding of β2-M [16], β2-M and HLA molecules variably expressed on the surface of tumor cells [17- 23]. Because the HLA class I antigen 203 are key component of the immune system, the recognition of tumor-specific antigen by cytotoxic T cell is dependent on intact HLA expression. Malignant cells with modified or lacking of HLA expression may escape from the normal host immune response and proliferate uncontrollably [24-26]. A structural defect of the HLA complex may also result in changes in epitope expression and increased release of β2-M in serum [27-30]. This mechanism is consistent with the observation that serum β2-M levels reflect tumor burden and cell turnover [27,28,31,32]. This mechanism also can explain why the mean β2-microglobulin levels in patients with breast, thyroid and liver cancer were significantly higher than that in patients with benign tumor in present study, the reason may be that the cancer cell burden and turnover more quickly than benign tumor.

We cannot explained the reason why the mean elevated β2-microglobulin level significantly higher in patients with breast, thyroid and liver cancer than that in patients with other solid cancer, but we noted that the breast cancer and thyroid cancer have same feature that the breast cancer and thyroid cancer both are glandular cancer and both are correlated with the estrogen receptor (ER), progesterone receptor (PR) and HER2/neu [33,34]. Whether β2-microglobulin have any correlation with the ER, PR and 222 HER2/neu in breast and thyroid cancer need further studying.

The another possibility of the mechanism responsible for an increase in β2-M expression during the progression of cancer is that the tumors contain three β2-M alleles instead of one. Recently, Nomura et al.[36] demonstrated that promoted growth of β2-M in human renal cell carcinomas while interrupting the β2-M signaling pathway lead to apoptosis of tumor cells Huang et al. [37] reported that β2-M is a signaling and growth promoting factor for human prostate cancer bone metastasis, β2-M stimulate growth and enhance osteocalcin(OC) and bone sialoprotein (BSP) gene expression in human prostate cancer cells by activating cyclic AMP(CAMP)-dependent protein kinase A signaling pathway Chen et al. [35] reported that β2-M may act as an effective growth promoting factor to facilitate tumor progression, invasion, and migration in oral cavity squamous cell carcinoma. Yang et al. [38] discovered that monoclonal antibodies (mAbs) specific to human β2-M induce apoptosis in vitro and were therapeutic in mouse models of myeloma and other hematological tumor cells via recruiting HMC class I molecules to lipid rafts and activating Lyn and PLCγ2, leading to activated JNK and inhibited P13K/Akt and ERK, compromised mitochondrial integrity, and caspase-9-dependent cascade activation [38]. Accordingly, these finding address 241 that β2-M must play a far-reaching function than just a housekeeping gene or role on stabilization and presentation of MHC class I molecule in cells, an elevated serum β2-M may become one of important diagnosis factor, prognostic factor and survival predictors. The correlation of β2-M with Development, progression and differentiation of tumor need further studying.

In conclusion, we found that the serum elevated level of β2-microglobulin in patients with breasts cancers, thyroid cancer and liver cancer have been observed to be significantly higher than that in the controls, suggesting that β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of important assistantly diagnostic factors in patients with these cancer.

Acknowledgements

This work was supported by grants of Natural Science Foundation of China (81060247).

References

1. Gresswell P, Springer T, Strominger JL, Tumer MJ, Grey HM, et al. (1974) Immunological identity of the small subunit of HLA antigens and β2-Microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci 71: 2123-2127.

2. Grey HM, Kubo RT, Colon SM, Poulak MD, Cresswell P, et al. (1973) The small subunit of HLA antigens is β2- microglobulin. J Exp Med 138: 1608-1612.

3. Karlsson FA, Groth T, Kege K, Wibell L, Peterson PA (1980) Tourover in humans of β2-microglobulin. Eur J Clin Invest 10: 293-300.

4. Hansen PB, Olsen NV (1989) Beta2-microglobulin in medical disease. Ugeskr Laeger 149: 2960-2962.

5. Wibell L (1978) The serum level and urinary excretion of β2-microglobulin in health and renal disease. Pathol Biol 26: 295-301.

6. Klein T, Levin I, Niska A, Koren R, Gal R, et al. (1996) Correlation between tumour and serum Beta 2-m expression in patients with breast cancer. Eur J Immunogenet 23: 417-423.

7. Tsimberidou AM, Kanjarjan HM, Wen S, O’Brien S, Cortes J, et al. (2008) The prognostic significance of serum beta2-microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res 14: 721-730.

8. Lee JK, Tsai SC, Hseh JF, Ho YJ, Sun SS, et al. (2000) Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma. Anticancer Research 20: 4765-4768.

9. Madj Z, Sendlovie I, Pinder SE, Ellis IO, Durrant LG (2005) Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 117: 248-255.

10. Higuchi Y, Togawa T, Moriya H, Hoshi K, Sato M, et al. (1996) Clinical evaluation of serum beta 2-microglobulin in squamous cell carcinoma of the head and neck. Jpn J Cancer Res 87: 1321-1326.

11. Poulakis N, Sardakou A, Rizos D, Phocas I, Kontozoglou T, et al. (1991) Total loss of MHC class I antigens in acute myeloid leukemia and the role of beta2-microglobulin subunit in the pathogenesis of acute myeloid leukemia. Leukemia 5: 2035-2041.

12. Aydiner A, Topuz E, Disci R, Yasasever A, Dincer M, et al. (1994) Serum tumor markers for detection of bone metastasis in breasts cancer patients. Eur J Clin Cancer Res 41: 721-730.

13. Selli C, Cozzolino F, Carrini M, Lenzi R, Vercelli D (1984) Serum Beta 2-microglobulin levels in patients with renal cell carcinoma. Urol Res 12: 261-263.

14. Tas F, Aydiner A, Aydiner V, Disci R, Topuz E (2000) Clinical usefulness of serum assays of carcinoembryonic antigen and beta 2- microglobulin in the detection of tumor recurrence and survival in breast cancer patients. Clin Cancer Res 6: 2161-2167.

15. Yuan Q, Liu L, et al. (2012) Serum β2—Microglobulin Levels in Patients with Various Solid Cancer. J Mol Biomark Diagn 5: 9929. doi:10.4172/2155-9929.52-007
diagnosis and discrimination of metastasis of lung cancer. Turkish Journal of Cancer 30: 148-155.

15. Vaishali N, Tupkari JV (2005) An estimation of serum β2-Microglobulin level in premalignant lesions/ conditions and squamous cell carcinoma: A clinicopathological study. Journal of Oral and Maxillofacial Pathology 9: 16-19.

16. Anil S, Beena VT, Nair RG, Vijaya kumar T (1996) Evaluation of serum β2-microglobulin in premalignant and malignant lesions of the oral cavity. Endodontics 79: 750-752.

17. Csiba A, Whitwell HL, Moore M (1984) Distribution of histocompatibility and leucocyte differentiation antigens in normal human colon and in benign and malignant colonic neoplasms. Br J Cancer 50: 699-709.

18. Fleming KA, Mc Michael A, Morton JA, Woods J, Mc Gee JO (1981) Distribution of HLA class I antigens in normal human tissue and in mammary cancer. J Clin Pathol 34: 779-794.

19. Turbitt ML, Mackie RM (1981) Loss of β2 microglobulin from the cell surface of cutaneous malignant and premalignant lesions. Br J Dermatol 104: 507-613.

20. Walton GR, Mc Cue PA, Graham SD (1986) β-2-microglobulins as a differentiation marker in bladder cancer. J Urol 136: 1197-1200.

21. Moller P, Herrmann B, Moldenhauer G, Momburg F (1987) Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grademalignancy. Int J Cancer 40: 32-39.

22. Moller P, Lammler B, Herrmann B, Otto HF, Moldenhauer G, et al. (1986) The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expression. Immunology 59: 411-417.

23. Woda BA, Racklin B, Rappaport H (1981) Altered expression of histocompatibility antigens on "B" large cell lymphomas. Blood 57: 802-804.

24. Hui K, Grossefeld F, Festenstein H (1984) Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature 311: 750-752.

25. Tanaka K, Isselbacher KJ, Khoury G, Jay G (1985) Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science 228: 26-30.

26. Zinkernagel RM, Doherty PC (1979) MHC-restricted cytoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function and responsiveness. Adv Immunol 27: 51-177.

27. Kahn-Perlies B, Boyer C, Arnold B, Sanderson AR, Ferrier P, et al. (1987) Acquisition of HLA class I W6/32 defined antigenic determinant by heavy chains from different species following association with bovine β2-microglobulin. J Immunol 138: 2190-196.

28. Ferrier P, Layet C, Caillot DH, Jordan BR, Lemonnier FA (1985) The association between murine β2 microglobulin and HLA class I heavy chains results in serologically detectable conformational changes of both chains. J Immunol 135: 1281-1287.

29. Rein RS, Seemann GH, Neefjes JJ, Hochstenbach FM, Starn NJ, et al. (1987) Association with β2-microglobulin controls the expression of transfected human class I genes. J Immunol 136: 1178-1183.

30. Santos-Aguado J, Bio PA, Fuhrmann U, Strominger JL, Barbosa JA (1987) Amino acid sequences in the α 1 domain and not glycosylation are important in HLA-A2/β2- microglobulin association and cell surface expression. Mol Cell Biol 7: 982-990.

31. Cresswell P, Springer T, Strominger JL, Turner MJ, Grey HM, et al. (1974) Immunological identity of the small subunit of HL-A antigens and β2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci 71: 2123-2127.

32. Plesner T, Karle H, Rubin B, Thomsen M (1978) Evidence for a change in the expression of β2-microglobulin associated membrane structures on leukaemic human cells. Clin Exp Immunol 3: 269-275.

33. Broom RJ, Tang P (2007) Changes in estrogen receptor (ER), progesterone receptor (PR) and HER2/neu status with times: discordance rates between primary metastatic breast pathology samples. American Society of Clinical Oncology 3: 45-48.

34. Lewy Ti (2001) Estrogen and progesterone receptors in neoplastic and non-neoplastic thyroid lesion. Endocr Pathol 12: 315-327.

35. Chen HC, Su CY, Chien CY, Huang CC, Chuang HC, et al. (2008) Over expression of β2-microglobulin is associated with poor survival in patients with oral cavity squamous cell carcinoma and contributes to oral cancer cell migration and invasion. Br J Cancer 99: 1453-1461.

36. Nomura T, Huang WC, Chau HE, Wu D, Xie Z, et al. (2006) Beta2-microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein and vascular endothelial growth factor axis. Clin Cancer Res 12: 7294-7305.

37. Huang WC, Wu D, Xie Z, Zhou HE, Nomura T, et al. (2006) Beta2-microglobulin is a signaling and growth-promoting factor for human prostate bone metastasis. Cancer Res 66: 9108-9116.

38. Yang J, Qian J, Zeweman M, Wang S, Lin P, et al. (2006) Targeting β2-Microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10: 295-307.

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world’s leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 200 Open Access Journals
- 15,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial); Scopus; DOAJ; EBSCO, Index Copernicus and Google Scholar etc.
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/pharma